Show simple item record

dc.contributor.authorAGRASO BUSTO, SARA 
dc.contributor.authorVARELA POSE, VANESA 
dc.contributor.authorFernández Nuñez, Natalia 
dc.contributor.authorFirvida Perez, Jose Luis 
dc.contributor.authorSantome, L.
dc.contributor.authorAfonso Afonso, Francisco Javier 
dc.contributor.authorAzpitarte Raposeiras, Cristina
dc.contributor.authorDE DIOS ALVAREZ, NOEMI 
dc.contributor.authorGarcia, J.
dc.contributor.authorCampos Balea, Begoña 
dc.contributor.authorAreses Manrique, María Carmen 
dc.contributor.authorPEREIRO CORBACHO, DIEGO 
dc.contributor.authorLazaro Quintela, Martín 
dc.date.accessioned2021-12-10T09:00:13Z
dc.date.available2021-12-10T09:00:13Z
dc.date.issued2019
dc.identifier.issn1556-0864
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15806
dc.description.abstractBackground Treatment with tyrosine kinasa inhibitors has been a revolution for the patients with non-small cell lung cancer and EGFR positive mutation, especially in patients with exon 19 deletions. Afatinib seems one of the best options of treatment. Method Retrospective study on patients from different hospitals in Galicia (Spain) diagnosed of metastasic lung adenocarcinoma with EGFR positive mutation who have received first line treatment with afatinib between July 2015 and September 2018 were included. Main objective was to compare our clinical experience concerning response rate, progression free survival and toxicity with published data. Result 45 Caucasians patients were included in our analysis (33 women, 12 men). Median age was 71.2 years (range 39-91 years) and 29 patients had never smoked. Exon 19 deletion was the most common mutation (41 patients, 91.1%). The objective overall response was 68.9% (95% CI: 82.4-55.3), complete responses were observed in 6 patients (13.3%) and partial responses were found in 25 patients (55.6%). Stable disease was observed in 8 patients (17.8%) and disease progression in 1 patient (2.2%), 5 patients have not been reevaluated (11.1%). Median progression free survival (PFS) was 27 months (95% CI: 14.8-39.1) and overall survival was not reached. Common adverse events grade 3/4 were mucositis and skin toxicity in 11 patients (24.4%) and diarrhea in 6 patients (13.3%), respectively. The dose was reduced in 28 patients (62.2%) and treatment was discontinued in 8 patients (17.8%) owing to adverse events. Conclusion Median PFS in our patients is 15 months longer than the information retrieved from differents studies with similar response rates and toxicity. This might be due to a majority of population with exon 19 deletion which, according to published data, seems to benefit more from afatinib than from other EGFR mutations.en
dc.language.isoenges
dc.titleEPI.14-15 Real World Clinical Experience of the Galician Lung Cancer Group: Afatinib in Patients with EGFR Positive Mutationes
dc.typePublicación de congresoes
dc.authorsophosAgraso Busto, S.
dc.authorsophosVarela, V.
dc.authorsophosFernandez, N.
dc.authorsophosFirvida, X. L.
dc.authorsophosSantome, L.
dc.authorsophosAfonso, J.
dc.authorsophosAzpiarte, C.
dc.authorsophosDe Dios Alvarez, N.
dc.authorsophosGarcia, J.
dc.authorsophosCampos, B.
dc.authorsophosAreses, M. C.
dc.authorsophosPereiro, D.
dc.authorsophosLazaro, M.
dc.identifier.doi10.1016/j.jtho.2019.08.2300
dc.identifier.sophos32066
dc.issue.number10es
dc.journal.titleJournal of Thoracic Oncologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigoes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Hospital do Salnés ::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Oncoloxía médica
dc.page.initialS1037es
dc.page.finalS1037es
dc.relation.publisherversionhttps://www.jto.org/article/S1556-0864(19)32983-1/pdfes
dc.rights.accessRightsembargoedAccesses
dc.subject.keywordCHUVIes
dc.subject.keywordCHUFes
dc.subject.keywordCHUOes
dc.subject.keywordHULAes
dc.subject.keywordCHUPes
dc.typefidesComunicaciones a congresoses
dc.typesophosComunicaciones a congresoses
dc.volume.number14es


Files in this item

This item appears in the following Collection(s)

Show simple item record